Rauwolscine — Alpha-Yohimbine (Yohimban Alkaloid · High-Potency Alpha-2 Antagonist)

Compound	Rauwolscine (Alpha-Yohimbine)
Chemical class	Alkaloid — Indole (Yohimban; Yohimbine C-3 Epimer)
CAS	131-03-3
Primary source	Rauwolfia serpentina (Indian snakeroot / sarpagandha), Pausinystalia johimbe
Key applications	Alpha-2 adrenoceptor antagonist (high potency), fat loss, athletic performance
Claim strength	Moderate
Typical form	Rauwolfia/Sarpagandha extract; isolated rauwolscine
Buy from Herbuno	Sarpagandha Extract Powder → Indian Snakeroot Liquid Extract (Water Soluble) - Rauvolfia serpentina →

Commercial source: Rauwolscine is commercially available as a co-constituent of Rauwolfia serpentina (sarpagandha) root extract and Pausinystalia johimbe bark extract. Isolated rauwolscine (≥98% HPLC) is available from specialist chemical suppliers. See sourcing options below. Traditional use: Rauwolfia serpentina (Sarpagandha in Ayurveda, meaning “snake root”) has been used in Indian traditional medicine for over 3,000 years for hypertension, anxiety, insomnia, and snakebite antidotes. The discovery of reserpine from Rauwolfia in the 1950s revolutionised psychiatric and cardiovascular pharmacology. Rauwolscine is a minor alkaloid in this complex alongside reserpine, ajmaline, and serpentine. Research trajectory: Rauwolscine (alpha-yohimbine) has attracted significant sports nutrition research as a higher-potency alpha-2 antagonist than yohimbine, enabling effective fat mobilisation and sympathomimetic effects at lower absolute doses. It is increasingly marketed as a “next-generation” yohimbine with improved potency-to-dose ratio. See sourcing options below.

---

Evidence for Rauwolscine Applications

Alpha-2 adrenoceptor antagonism (3–5x yohimbine potency): Rauwolscine has approximately 3–5-fold higher binding affinity for alpha-2 adrenoceptors than yohimbine due to its different C-3 stereochemistry enabling superior receptor fit. This higher potency translates to equivalent physiological effects (fat mobilisation, sympathomimetic stimulation) at lower absolute doses (1–3 mg rauwolscine vs 5–20 mg yohimbine). Claim strength: Moderate (mechanism established; human-specific comparison RCTs absent).

Fat loss and lipolysis: As with yohimbine, rauwolscine’s alpha-2 antagonism in adipose tissue removes the alpha-2-mediated brake on lipolysis. At lower doses than yohimbine, similar lipolytic effects are expected. Human body composition studies specifically for rauwolscine are limited; extrapolation from yohimbine mechanism is the primary evidence basis. Claim strength: Moderate.

Serotonin receptor activity: Rauwolscine also has antagonist activity at 5-HT2A serotonin receptors, which may contribute to mood effects and appetite modulation beyond its adrenergic activity. This serotonergic component distinguishes rauwolscine’s pharmacological profile from pure alpha-2 antagonists. Claim strength: Moderate.

---

Dosage & Formulator Specification

Typical supplement dose: 1–3 mg rauwolscine per serving (vs 5–20 mg yohimbine for equivalent alpha-2 antagonism). Pre-workout or fat burner formulations typically include 1–2 mg rauwolscine per serving. No large-scale human RCTs have established a dose-response for rauwolscine specifically; doses are extrapolated from yohimbine pharmacology with a 3–5x potency correction.

The same cardiovascular safety advisory language as yohimbine applies in full to rauwolscine — at its higher potency, cardiovascular adverse effects may manifest at lower absolute doses than yohimbine. Contraindications: hypertension, cardiovascular disease, anxiety disorders, MAOIs, antidepressants. Regulatory status: equivalent to yohimbine in markets that restrict alpha-yohimbine/rauwolscine content. Verify current market-specific limits.

---

Frequently Asked Questions — Rauwolscine

Is rauwolscine safer than yohimbine because lower doses are used?
Not necessarily. Higher receptor affinity means rauwolscine achieves equivalent alpha-2 receptor occupancy at lower doses — but equivalent receptor occupancy produces equivalent cardiovascular effects. The safety profile is not meaningfully different from yohimbine at pharmacologically equivalent doses. The lower absolute dose required does reduce the practical risk of accidental overdose from imprecise measurement, which is a practical formulation advantage.

What is Rauwolfia serpentina extract and how does it differ from sarpagandha?
Rauwolfia serpentina and sarpagandha refer to the same plant — the Indian snakeroot. The pharmaceutical-significant alkaloid from Rauwolfia is reserpine, which depletes monoamine neurotransmitters and was the first effective antihypertensive and antipsychotic drug. Rauwolscine is a minor co-alkaloid. Sarpagandha extract for supplement use should specify which alkaloid fraction is being standardised — total alkaloids, reserpine, or rauwolscine — as these have entirely different pharmacological profiles.

Is reserpine from Rauwolfia a concern in sarpagandha extract?
Yes — reserpine (the dominant pharmacological alkaloid in Rauwolfia) is a potent monoamine depleter with severe adverse effects including depression, sedation, and paradoxical hypertension on abrupt withdrawal. Sarpagandha extract used for rauwolscine content must specify reserpine limits by HPLC. High-reserpine preparations of Rauwolfia are pharmaceutical drugs, not supplements. Formulators must confirm reserpine content is negligible in any rauwolscine-targeted Rauwolfia extract.

Can rauwolscine and yohimbine be combined in one formulation?
Yes — some premium sports nutrition fat burner products combine rauwolscine (1–2 mg) with yohimbine (5–10 mg) for dual alpha-2 blockade at overlapping but distinct binding sites. The combination has theoretical additive alpha-2 antagonism. Cardiovascular risk is additive; the same contraindications and advisory language apply with enhanced emphasis given the combined stimulant load.

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery